Champions Oncology (CSBR) Reports Q4 Loss of $0.15/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Champions Oncology Reports 38% Revenue Growth for Fiscal Year Ended April 30, 2017
July 27, 2017 4:01 PM EDTHACKENSACK, N.J., July 27, 2017 /PRNewswire/ --Â Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the fourth quarter and year ended April 30, 2017.
Fourth Quarter and Recent Business Highlights:
Record annual revenue of $15.4M, a 38% year over year increase Record TOS segment revenue of $13.7M, a 49% year-over-year increase Record annual TOS bookings, a 51% year over year increase Opened new lab facility in Rockville, Maryland, doubling... More